Volume 24, Number 4—April 2018
Research
Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017
Table 4
Antibody titers in survivors of influenza A(H7N9) during the acute phase and at 3 follow-up points, China, 2017*
Patient no. |
HI/NI/MN/IgG/IgA titers | |||
---|---|---|---|---|
Acute phase |
Follow-up visit 1 |
Follow-up visit 2 |
Follow-up visit 3 |
|
1 | 20/5/5/50/25 | 10/80/10/1600/50 | 10/40/10/800/25 | 10/20/10/800/25 |
2 | 20/5/5/50/50 | 10/10/20/1600/100 | 10/10/20/400/50 | 10/5/20/400/50 |
3 | 160/20/5/400/200 | 320/160/160/6400/50 | 160/160/320/6400/25 | 40/40/160/1600/25 |
4 | 40/320/20/400/25 | 40/320/20/3200/100 | 20/40/10/1600/25 | 5/10/10/800/25 |
5 | 5/5/5/100/25 | 640/5120/640/25600/1600 | 320/320/320/12800/800 | 40/80/320/3200/400 |
6 | 20/20/5/400/50 | 320/1280/160/3200/200 | 160/160/640/800/100 | 20/40/160/800/100 |
7 | 40/40/5/200/200 | 320/320/160/6400/800 | NA | NA |
8 | 40/5/5/50/25 | 320/320/40/1600/400 | 80/80/40/1600/200 | 20/20/40/800/100 |
9 | 5/5/5/100/25 | 80/1280/160/51200/400 | 40/40/160/6400/50 | 40/40/160/6400/50 |
10 | 1280/2560/160/12800/1600 | 160/2560/160/51200/800 | 80/320/320/12800/400 | 40/80/320/3200/200 |
11 | 40/10/5/100/100 | 80/80/80/6400/400 | 40/20/40/400/200 | 20/20/80/1600/100 |
12 | 40/40/5/800/50 | 80/5120/40/25600/200 | NA | NA |
13 | 20/10/5/400/100 | 160/1280/160/12800/400 | 80/320/320/3200/200 | 40/80/160/1600/200 |
14 | 5/5/5/50/25 | 160/160/160/3200/400 | 40/40/40/800/100 | 20/20/40/800/100 |
15 | 160/5120/160/3200/800 | 80/5120/160/3200/200 | 40/80/160/1600/25 | 20/80/160/1600/25 |
16 | 640/5120/160/12800/400 | 160/640/80/6400/800 | 80/320/160/3200/400 | 40/80/160/1600/400 |
17 | 20/160/5/100/25 | 160/320/80/12800/400 | 80/80/80/1600/400 | 40/40/80/1600/400 |
18 | 80/5/80/100/25 | 80/1280/80/1600/50 | 40/80/160/800/25 | 20/40/160/800/25 |
19 | 40/80/10/200/25 | 320/2560/640/25600/25 | 40/160/160/1600/25 | 20/40/160/1600/25 |
20 | 40/640/20/800/200 | 320/5120/640/3200/200 | 160/160/1280/6400/200 | NA |
21 | NA | 160/5120/40/6400/100 | 40/160/40/1600/25 | 20/80/40/1600/25 |
22 | 20/640/40/25/25 | 80/1280/40/3200/100 | 40/320/80/800/25 | 20/20/40/400/25 |
23 | 20/40/5/1600/200 | 320/5120/160/25600/800 | 80/160/160/3200/400 | 80/80/160/1600/400 |
24 | NA | 80/640/40/12800/100 | 40/160/160/3200/50 | 20/40/40/1600/50 |
25 | NA | 40/80/40/3200/50 | 20/20/40/1600/25 | 5/10/40/400/25 |
*HI, hemagglutination inhibition; MN, microneutralization; NA, not available; NI, neuraminidase inhibition.
1These authors contributed equally to this article.